# Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia

> **NCT00660036** · PHASE1 · TERMINATED · sponsor: **University of Pittsburgh** · enrollment: 5 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Gemtuzumab ozogamicin
- **DRUG:** Mitoxantrone
- **DRUG:** Etoposide

## Key facts

- **NCT ID:** NCT00660036
- **Lead sponsor:** University of Pittsburgh
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-09
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** due to new safety information
- **Last updated:** 2016-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00660036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00660036, "Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT00660036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*